РЕВАСКУЛЯРИЗАЦИЯ ПОЧЕК И ОТДАЛЁННАЯ СЕРДЕЧНО-СОСУДИСТАЯ ВЫЖИВАЕМОСТЬ БОЛЬНЫХ С АТЕРОСКЛЕРОТИЧЕСКОЙ ИШЕМИЧЕСКОЙ БОЛЕЗНЬЮ ПОЧЕК

The prospective investigation of 185 patients (118 men and 67 women in the age of 35–79 years (on the average 60±9 years) with atherosclerotic renovascular disease was carried out. The disease was detected by one- (62%) and two- (38%) hemodynamic value (>50%) of renal artery stenosis. Renal function, arterial pressure, cardiovascular death cases were estimated in 4 groups of patients during the period of 2,5–126 months (on the average 33 months). The patients of the first group (n=103) were undergone the renal revascularization (51 open and 80 endovascular). The patients of the second group (n=20) were after combined open renal revascularization (25) and after performed reconstruction of abdominal aorta and its branches and lower extremities arteries concerning aneurysmatic and occlusive lesions. The patients of the third group (n=19) had only reconstruction of lower extremities arteries concerning their ischemia without renal revascularization. The patients of the fourth group (n=43) haven’t been operated because of the refusal of intervention. The lowest rate of survival was in the fourth group, who used the conservative therapy. Long-term survival didn’t differ after open and endovascular therapy. The Koks regression analysis showed, that the improvement of long-term survival of the patients was associated with renal revascularization [Exp (B)=0,25, p<0,001] and didn’t depend on the method of renal arteries reconstruction. A strategy of careful selection of patients with the application of interdisciplinary approach should be the base of clinical practice in renovascular disease.

ишемическая болезнь почек, открытая и эндоваскулярная реваскуляризация почек, сердечно-сосудистая выживаемость, ischemic kidney disease, open and endovascular renal revascularization, cardiovascular survival

1. Игнашов А. М., Смирнов А. В., Добронравов В.Аи др. Ишемическая болезнь почек // Нефрология. 2004. Т. 8, прил. 2. С. 19–27.

2. Смирнов А. В., Добронравов В. А., Каюков И. Г. Кардиоренальный континуум: основы превентивной терапии // Нефрология. 2005. № 3. С. 7–15.

3. Смирнов А. В., Есаян А. М., Каюков И. Г.и др. Современные подходык замедлению прогрессирования хронической болезни почек // Нефрология. 2004. № 3. С. 89–99.

4. Семенов Д. В., Смирнов А. В., Кириллова Е. В.и др. Допплерографическая оценка артериального кровотокаи изменения функции почеку больныхс атеросклерозом почечных артерий после реваскуляризации // Нефрология. 2012. № 1. С. 45–51.

5. Смирнов А. В., Шилов Е. М., Добронравов В. А.и др. Национальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактикии подходык лечению // Нефрология. 2012. № 1. С. 89–115.

6. Bax L., Woittiez A. J., Kouwenberg H. J. et al. Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: randomized trial (STAR) // Ann. Intern. Med. 2009. Vol. 150, № 12, 840–848. P. W150–W151.

7. Caps M. T., Zierler R. E., Polissar N. L. et al. Risk of atrophy in kidney with atherosclerotic renal artery stenosis // Kidney Int. 1998. Vol. 53. P. 735–742.

8. Erdoes L. S., Berman S. S., Hunter G. C., Mills J. L. Comparative analysis of percutaneous transluminal angioplasty and operation for renal revascularisation // Am. J. Kid. Dis. 1996. Vol. 27, № 4. P. 496–503.

9. Go A. S., Chertow G. M., Dongjie Fan M. P.H. et al. Chronic kidney disease and the risk of death, cardiovascular events and hospitalization // N. Engl. Med. J. 2004. Vol. 351, № 13. P. 1296–1305.

10. Hansen K. J., Wilson D. B., Dean R. H. Atherosclerotic renovascular disease and ischemic nephrophaty // R. B. Rutherford «Vascular Surgery» 2005, W. B. Saunders company, Fifth Ed., 1805–1824.

11. Herrmann S. M., Textor S. C. Diagnostic criteria for renovascular disease: where are we now? // Nephrol. Dial. Transplant. 2012. Vol. 27, № 7. P. 2657–2663.

12. Iantorno M., Pola R., Schinzari F. et al. Association between altered circadian blood pressure profile and cardiac end-organ damage in patients with renovascular hypertension // Cardiology. 2003. Vol. 100, № 1. P. 114–119.

13. Lao D., Parasher P. S., Cho K. et al. Atherosclerotic renal artery stenosis — diagnosis and treatment // Mayo Clinic Proc. 2011. Vol. 86, № 7. P. 649–657.

14. Losito A., Errico R., Santirosi P. et al. Long-term follow-up of atherosclerotic renovascular disease. Beneficial effect of ACE inhibition // Nephr. Dial. Transpl. 2005. Vol. 20, № 8. P. 1604–1609.

15. McDowall P., Kalra P. A., O’Donoghue D. J. et al. Risk of morbidity from renovascular disease in elderly patients with congestive cardiac failure // Lancet 1998. Vol. 352, № 9128. P. 656.

16. National Kidney Foundation. K/DOKI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification // Am. J. Kid. Dis. 2002. Vol. 39 (suppl.). P. S1–S266.

17. Wheatley K., Ives N., Gray R. et al. Revascularisation versus medical therapy for renal artery stenosis (ASTRAL) // N. Engl. J. Med. 2009. Vol. 361, № 20. P. 1953–1962.

18. Wright J. R., Shurrab A., Cooper A. et al. Left ventricular morphology and function in patients with atherosclerotic renovascular disease // J. Am. Soc. Nephrology. 2005. Vol. 16, № 19. P. 2746–2753.